Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000703 · ClinicalTrials.gov registry record · NA

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

A NA study of HIV Infections and Lymphoma, Non-Hodgkin, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
45
Enrollment target
14
Study locations

NCT00000703: Completed NA study of HIV Infections and Lymphoma, Non-Hodgkin, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000703 is a NA study of HIV Infections and Lymphoma, Non-Hodgkin that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 45 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000703, a NA study of HIV Infections and Lymphoma, Non-Hodgkin, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
14
Study locations

Study Summary

To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma. Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results have not been satisfactory. This study will show whether the combination of chemotherapy, radiation, and AZT is more effective and less toxic than previously used treatments.

Conditions Studied

HIV Infections Lymphoma, Non-Hodgkin

Interventions

  • DRUG Cyclophosphamide
  • DRUG Allopurinol
  • DRUG Doxorubicin hydrochloride
  • DRUG Bleomycin sulfate
  • DRUG Vincristine sulfate

Study Locations (14)

New York

  • Bellevue Hosp / New York Univ Med Ctr - New York
  • Saint Luke's - Roosevelt Hosp Ctr - New York
  • Mount Sinai Med Ctr - New York
  • Univ of Rochester Medical Center - Rochester

California

  • Los Angeles County - USC Med Ctr - Los Angeles
  • UCLA CARE Ctr - Los Angeles
  • San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco

Louisiana

  • Charity Hosp / Tulane Univ Med School - New Orleans
  • Louisiana State Univ Med Ctr / Tulane Med School - New Orleans
  • Tulane Univ School of Medicine - New Orleans

District of Columbia

  • George Washington Univ Med Ctr - Washington D.C.

Massachusetts

  • Univ of Massachusetts Med Ctr - Worcester

Pennsylvania

  • Milton S Hershey Med Ctr - Hershey

South Carolina

  • Julio Arroyo - West Columbia

Trial Details

FieldValue
Enrollment Target 45 participants
Est. Completion 1990-03
Phase NA
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000703 record still lists

NCT00000703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT00000703 lists 14 locations in 7 states (New York, California, Louisiana).

Frequently Asked Questions

What is clinical trial NCT00000703 about?

NCT00000703 is a clinical study titled "Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members". To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma. Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results have not been satisfactory. This study will show whether ...

What is the current status of trial NCT00000703?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. Estimated completion is 1990-03.

What conditions does trial NCT00000703 study?

This clinical trial studies the following conditions: HIV Infections, Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT00000703?

The interventions under investigation include: Cyclophosphamide (DRUG), Allopurinol (DRUG), Doxorubicin hydrochloride (DRUG), Bleomycin sulfate (DRUG), Vincristine sulfate (DRUG).

Who is sponsoring clinical trial NCT00000703?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000703 being conducted?

This trial has 14 study locations across California, District of Columbia, Louisiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000703's enrollment target sits among peer trials

45 377th of 542 higher than 164 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Related registry views

Source: ClinicalTrials.gov NCT00000703, the US trial registry maintained by the National Library of Medicine. NCT00000703 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.